Video

Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Andrew T. Kuykendall, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the addition of fedratinib (Inrebic) to the treatment paradigm in myelofibrosis.

Fedratinib is a relatively old drug that went through extensive clinical trials and was tested in many patients several years ago. After going through phase III clinical trials in ruxolitinib (Jakafi) patients with myelofibrosis, fedratinib was put on hold.

Despite its setbacks, fedratinib experienced a resurgence where the safety signals were reexamined, and researchers took a closer look at its efficacy. Now, fedratinib is approved to treat patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, giving patients the option of a second JAK inhibitor.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD